Evidence map›Paper›PMID 37205636›Full record

ArticleCancer research2023

Periostin+ Stromal Cells Guide Lymphovascular Invasion by Cancer Cells.

Jamie L Null, Dae Joong Kim, James V McCann, Patcharin Pramoonjago, Jay W Fox, Jianhao Zeng, Pankaj Kumar, Lincy Edatt, Chad V Pecot, Andrew C Dudley

Open access · greenAbstract read
In one paragraph

Article in Cancer research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
3.7field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Targeting Tumor-Associated Macrophages and Cancer-Associated Fibroblasts to Overcome Therapeutic Resistance in Hepatocellular Carcinoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026
    Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Jamie L NullDepartment of Microbiology, Immunology, and Cancer Biology, The University of Virginia, Charlottesville, Virginia.ORCID 0000-0003-3418-3995
Dae Joong KimDepartment of Microbiology, Immunology, and Cancer Biology, The University of Virginia, Charlottesville, Virginia.ORCID 0000-0002-8646-5962
James V McCannDepartment of Cell Biology, Johns Hopkins University, Baltimore, Maryland.ORCID 0000-0003-0639-3215
Patcharin PramoonjagoDepartment of Pathology, The University of Virginia, Charlottesville, Virginia.ORCID 0000-0002-6138-6985
Jay W FoxDepartment of Microbiology, Immunology, and Cancer Biology, The University of Virginia, Charlottesville, Virginia.ORCID 0000-0003-4600-1132
Jianhao ZengDepartment of Microbiology, Immunology, and Cancer Biology, The University of Virginia, Charlottesville, Virginia.ORCID 0000-0002-1026-729X
Pankaj KumarUVA Bioinformatics Core, Charlottesville, Virginia.ORCID 0000-0002-8702-8879
Lincy EdattLineberger Comprehensive Cancer Center, Chapel Hill, North Carolina.ORCID 0000-0001-7594-4012
Chad V PecotLineberger Comprehensive Cancer Center, Chapel Hill, North Carolina.ORCID 0000-0002-5250-2999
Andrew C DudleyDepartment of Microbiology, Immunology, and Cancer Biology, The University of Virginia, Charlottesville, Virginia.ORCID 0000-0002-2663-1949
University of Virginia · USUniversity of North Carolina at Chapel Hill · USJohns Hopkins University · USScience Factory · US

Funding

Women's Oncology Program - WONP30CA044579 · NCI · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI Jay William FOX · 1987 to 2026
$72.1M
Cancer Research Training Program: From Molecular Mechanisms to Therapeutic StrategiesT32CA009109 · NCI · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI Andrew Carl Dudley, Melanie R Rutkowski · 1985 to 2026
$13.9M
Targeting the vasculature to enhance anti-tumor immunityR01CA177875 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Andrew Carl Dudley · 2014 to 2026
$4.5M
Tumor Endothelial Cell Regulation of Pro-Metastatic Fibrin MatricesR01CA258451 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DUDLEY, ANDREW CARL, PECOT, CHAD V · 2021 to 2025
$2.9M
Fibroblast lineage tracing in metastatic and pre-metastatic microenvironmentsF31CA247407 · NCI · UNIVERSITY OF VIRGINIA · PI NULL, JAMIE L · 2020 to 2022
$87k
NCI NIH HHS F31 CA247407NCI NIH HHS P30 CA044579NCI NIH HHS R01 CA177875NCI NIH HHS R01 CA258451NCI NIH HHS T32 CA009109
6 · The paper itself

Abstract

Cancer cell dissemination to sentinel lymph nodes is associated with poor patient outcomes, particularly in breast cancer. The process by which cancer cells egress from the primary tumor upon interfacing with the lymphatic vasculature is complex and driven by dynamic interactions between cancer cells and stromal cells, including cancer-associated fibroblasts (CAF). The matricellular protein periostin can distinguish CAF subtypes in breast cancer and is associated with increased desmoplasia and disease recurrence in patients. However, as periostin is secreted, periostin-expressing CAFs are difficult to characterize in situ, limiting our understanding of their specific contribution to cancer progression. Here, we used in vivo genetic labeling and ablation to lineage trace periostin+ cells and characterize their functions during tumor growth and metastasis. Periostin-expressing CAFs were spatially found at periductal and perivascular margins, were enriched at lymphatic vessel peripheries, and were differentially activated by highly metastatic cancer cells versus poorly metastatic counterparts. Surprisingly, genetically depleting periostin+ CAFs slightly accelerated primary tumor growth but impaired intratumoral collagen organization and inhibited lymphatic, but not lung, metastases. Periostin ablation in CAFs impaired their ability to deposit aligned collagen matrices and inhibited cancer cell invasion through collagen and across lymphatic endothelial cell monolayers. Thus, highly metastatic cancer cells mobilize periostin-expressing CAFs in the primary tumor site that promote collagen remodeling and collective cell invasion within lymphatic vessels and ultimately to sentinel lymph nodes. SIGNIFICANCE: Highly metastatic breast cancer cells activate a population of periostin-expressing CAFs that remodel the extracellular matrix to promote escape of cancer cells into lymphatic vessels and drive colonization of proximal lymph nodes.

Indexed as

Breast NeoplasmsLymph NodesFemaleHumansNeoplasm InvasivenessStromal Cells

Identifiers

PMID37205636
PMCPMC10330490
OpenAlexW4377090247

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.